The Shotlee Journal
Expert insights on GLP-1 medications, peptide therapy, and evidence-based approaches to weight management.
Loading articles...
Showing 9 / 1263 articles
Novo Nordisk introduces the 'There's Only One Ozempic' campaign, reuniting comedy duo Justin Long and John Hodgman to spotlight Ozempic's unique FDA-approved benefits for type 2 diabetes. The effort uses humor and education to distinguish genuine Ozempic (semaglutide) from unapproved compounded versions. It encourages vital conversations between patients and healthcare providers.
One-third of South Africans live with obesity, driving new clinical guidelines that endorse GLP-1 drugs like Ozempic, Mounjaro, and Wegovy. These medications lower blood sugar, slow digestion, and promote fullness but face affordability barriers. Experts urge political action for broader access.
Daily tasks like banking and food delivery are fully digital, yet healthcare remains outdated. In Nigeria, 47.7% of educated adults self-medicate antibiotics, driving antimicrobial resistance deaths. Digital platforms and GLP-1 weight loss programs offer seamless, compliant solutions.
Semaglutide-based Ozempic has become a weight loss sensation beyond diabetes treatment. Yet, over 1,800 US lawsuits signal serious risks including gastroparesis, bowel issues, and vision loss from NAION. UK and Irish prescribers face growing negligence exposure.
GLP-1 receptor agonists drive effective weight loss but can accelerate bone and muscle loss in postmenopausal women. Aging naturally reduces muscle mass and bone density, and rapid weight loss amplifies these risks. Protect your health with resistance exercise, adequate protein, and comprehensive monitoring.
GLP-1 drugs mimic natural hormones to reduce hunger, slow digestion, and control blood sugar, aiding weight loss and type 2 diabetes. In Malaysia, over 54% of adults are overweight or obese, prompting Health Ministry rollout for vulnerable groups in 2026. Understand benefits, risks, and safe use guidelines.
GLP-1 medications extend beyond diabetes and weight loss to enhance overall metabolic health. They improve insulin sensitivity, curb chronic inflammation, and optimize cholesterol levels. Patients often report sustained energy and better wellness.
Three suspects face robbery charges after stealing $16,000 worth of GLP-1 weight loss drugs, including Ozempic, Mounjaro, and Trulicity, from a pharmacy delivery in Bensalem, Pennsylvania. Police quickly apprehended the men from New York following a high-speed chase. The incident highlights surging demand for these popular medications.
Prof Jim Mann cautions against broad funding for Wegovy, urging focus on high-risk patients like those with heart disease or diabetes. He emphasizes integrating GLP-1 medications into a national obesity strategy with mandatory nutritional support to prevent weight regain. Early data highlights side effect risks and the need for dietary counseling.
